SubHero Banner

Brilinta® (ticagrelor) – New indication

May 28, 2020 - The FDA approved AstraZeneca’s Brilinta (ticagrelor), to reduce the risk of a first myocardial infarction (MI) or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of Brilinta was established in a population with type 2 diabetes mellitus (T2DM).

Download PDF